Premium
Antibody Recruiting Small Molecules: A New Option for Prostate Tumor Therapy by PSMA Targeting
Author(s) -
Küchenthal ChristianH.,
Maison Wolfgang
Publication year - 2010
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.201000190
Subject(s) - prostate cancer , glutamate carboxypeptidase ii , effector , antibody , cancer research , immune system , small molecule , prostate , chemistry , cancer , endogeny , medicine , immunology , biochemistry
The membrane protein PSMA is a valuable marker for prostate cancer and can be used to direct PSMA‐specific small molecules to prostate cancer cells. If these PSMA ligands are conjugated to appropriate effector domains, endogenous antibodies are recruited and a selective immune response against the cancer cells is instigated.